Kauliv
Teriparatide biosimilar developed by Strides Pharma. Reference product Forsteo (Forteo in the United States).
Brands by market: Kauliv (EU) · Commercial partner or holder: Strides Pharma
FDAnot listed
EMAJan 2023authorised
CDSCOnot listed
EDEnot listed
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union · Kauliv
European Medicines Agency and European CommissionApprovedBrand
Kauliv
Holder or applicant
Strides Pharma (Cyprus) Limited
Pathway
Centralised (Article 10(4))
Approved
Jan 2023
Application or permission
EMEA/H/C/004932
Presentations
see SmPC
Source
S017
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Chronology
- EMAJan 2023Authorised by the European Commission
Sources
S017EMA, medicines data table (medicines-output-medicines-report_en.xlsx) Primary (regulator)
Planning teriparatide biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.